Quantitative multimodality imaging in cancer research and therapy
about
Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging.MR Imaging Biomarkers in Oncology Clinical TrialsPredicting in vivo glioma growth with the reaction diffusion equation constrained by quantitative magnetic resonance imaging data.Cancer stratification by molecular imaging.Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancerRepeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.Quantitative Multi-Parametric Magnetic Resonance Imaging of Tumor Response to Photodynamic Therapy.Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.Imaging technologies from bench to bedside.Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.Advanced bioanalytics for precision medicine.Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.Strong correlation between early stage atherosclerosis and electromechanical coupling of aorta.Diffusion-weighted multiparametric MRI for monitoring longitudinal changes of parameters in rabbit VX2 liver tumors.Mathematical Modeling of the Function of Warburg Effect in Tumor Microenvironment.Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver MetastasesNovel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer
P2860
Q30299954-82648F3D-914F-415D-BB84-9073B6152E92Q30364608-EC8D4859-CCED-4335-8ECE-F610C02D354CQ30964764-56CDC537-70B9-4DFF-8C9E-E62A71125055Q35380664-38722C0E-EF43-4E61-A211-3ADA8C51DA70Q35762255-F90B8395-ED8E-4394-9BB6-58F2429E201FQ35802452-4BEA8256-5C46-4D78-BE4F-B9319DF2B6EBQ36184341-9B074C6B-A410-4878-9737-26CD7EAC2340Q36427037-9DBB9DB7-A902-43CE-ACF4-31A7F7C0D4CEQ37559704-9533781D-3738-4C0A-838C-DE88FF3C425EQ38888255-2A77CC93-1618-4223-8CA4-F49828FA2916Q38968830-E7A27E79-039A-4FD7-AB25-DA2487DB297FQ42691434-DC0578E7-DEBA-4363-B56D-B31CC555C502Q47287018-D90AA2A1-7681-447E-9664-F1621B64A048Q47656712-88F4DED5-31D4-4B56-A335-E584D632D746Q47959144-B68DA43A-7452-4002-89D7-2B88B3034B83Q51446926-A953A133-BD2C-47DB-92D4-3269B0EECBA5Q52984970-0E5C0A9A-A030-4583-9AB8-AB063DD24C29Q55209479-16A26522-65D5-4F8F-A778-980042AEBD69Q58007428-F1E95519-DDB7-4D58-8459-7C7F1731D965Q58593068-6DACA0DE-5A32-4190-B21B-F4AB795FD338
P2860
Quantitative multimodality imaging in cancer research and therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quantitative multimodality imaging in cancer research and therapy
@en
Quantitative multimodality imaging in cancer research and therapy.
@nl
type
label
Quantitative multimodality imaging in cancer research and therapy
@en
Quantitative multimodality imaging in cancer research and therapy.
@nl
prefLabel
Quantitative multimodality imaging in cancer research and therapy
@en
Quantitative multimodality imaging in cancer research and therapy.
@nl
P2860
P1476
Quantitative multimodality imaging in cancer research and therapy
@en
P2093
C Chad Quarles
P2860
P304
P356
10.1038/NRCLINONC.2014.134
P407
P577
2014-08-12T00:00:00Z